Pirtobrutinib - Generic Drug Details

What are the generic drug sources for pirtobrutinib and what is the scope of patent protection?

Pirtobrutinib is the generic ingredient in one branded drug marketed by Loxo Oncol and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pirtobrutinib has one hundred and four patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for pirtobrutinib

International Patents:	104
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	23
Clinical Trials:	54
What excipients (inactive ingredients) are in pirtobrutinib?	pirtobrutinib excipients list
DailyMed Link:	pirtobrutinib at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for pirtobrutinib

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for pirtobrutinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
SWOG Cancer Research Network	PHASE3
National Cancer Institute (NCI)	PHASE3
Fondazione Italiana Linfomi - ETS	PHASE2

See all pirtobrutinib clinical trials

Pharmacology for pirtobrutinib

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Bruton's Tyrosine Kinase Inhibitors Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for pirtobrutinib

L01EL	Bruton's tyrosine kinase (BTK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for pirtobrutinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes			Y	Y
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No			Y	Y

EU/EMA Drug Approvals for pirtobrutinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Jaypirca	pirtobrutinib	EMEA/H/C/005863Treatment of mantle cell lymphoma (MCL)	Authorised	no	no	no	2023-10-30

International Patents for pirtobrutinib

Country	Patent Number	Title	Estimated Expiration
France	24C1009
China	114591242
Ukraine	127863	СПОЛУКИ, ЯКІ МОЖНА ЗАСТОСОВУВАТИ ЯК ІНГІБІТОРИ КІНАЗИ
Singapore	11201805044W	COMPOUNDS USEFUL AS KINASE INHIBITORS
South Africa	202100544	COMPOUNDS USEFUL AS KINASE INHIBITORS
United Kingdom	201613945
Portugal	3390395

Supplementary Protection Certificates for pirtobrutinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3390395	122024000010	Germany		PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031
3390395	CA 2024 00006	Denmark		PRODUCT NAME: PIRTOBRUTINIB; REG. NO/DATE: EU/1/23/1738 20231031
3390395	2490003-7	Sweden		PRODUCT NAME: PIRTOBRUTINIB; REG. NO/DATE: EU/1/23/1738 20231031
3390395	4/2024	Austria		PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 (MITTEILUNG) 20231031
3390395	24C1009	France		PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031
3390395	PA2024506	Lithuania		PRODUCT NAME: PIRTOBRUTINIBAS; REGISTRATION NO/DATE: EU/1/23/1738 20231030
3390395	C20240004	Finland

Market Dynamics and Financial Trajectory for Pirtobrutinib

Last updated: February 19, 2026

Pirtobrutinib (formerly known as LOXO-305) is an investigational Bruton’s tyrosine kinase (BTK) inhibitor developed by Eli Lilly. It targets B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Its unique non-covalent binding distinguishes it from covalent BTK inhibitors like ibrutinib. The compound is in late-stage clinical trials, primarily evaluating its efficacy and safety profile in relapsed or refractory B-cell cancers.

Regulatory and Development Status

• Phase: Pirtobrutinib is in Phase 3 clinical trials as of 2023, specifically the BRUIN trial program.
• Indications: Focuses on CLL/SLL, MCL, and other B-cell malignancies resistant to covalent BTK inhibitors.
• Regulatory filings: No FDA approval as of 2023; pending data from ongoing trials influencing potential submission timelines.

Market Drivers

Unmet Medical Need

• Resistance to existing BTK inhibitors (ibrutinib, acalabrutinib) increases demand for alternatives.
• Non-covalent binding offers potential advantages for patients with resistance mutations, such as C481S.

Competitive Landscape

Drug	Type	Approval Status	Market Penetration	Key Features
Ibrutinib (Imbruvica)	Covalent BTK inhibitor	Approved, 2013	Largest sales	First-in-class, oral, approved for many B-cell cancers
Acalabrutinib (Calquenza)	Covalent BTK inhibitor	Approved, 2017	Growing	Selectivity for BTK, fewer off-target effects
Zanubrutinib (Bruksvia)	Covalent BTK inhibitor	Approved, 2019	Increasing	Improved safety profile
Pirtobrutinib	Non-covalent BTK inhibitor	Phase 3 pending	Limited	Designed for resistance cases

Market Size and Revenue Potential

• The global hematologic oncology market valued at approximately USD 16 billion in 2022.
• BTK inhibitor segment accounted for USD 8 billion, expected to grow at compound annual growth rate (CAGR) of 8% through 2030.
• Pirtobrutinib’s potential capture depends on trial outcomes and competitive positioning.

Pricing and Reimbursement

• Covalent BTK inhibitors are priced between USD 70,000 and USD 100,000 annually per patient.
• Pirtobrutinib’s pricing could mirror or slightly undercut current therapies to penetrate resistant patient segments.
• Reimbursement decisions will influence market access, contingent on demonstrated clinical benefits and safety.

Financial Trajectory

Development Costs and Investment

• Eli Lilly dedicated an estimated USD 300 million to clinical development phases encompassing multiple trials.
• Additional costs include commercialization, regulatory compliance, and post-marketing surveillance.

Revenue Projections

Scenario	Assumptions	5-Year Revenue Estimate
Optimistic	Successful trials, rapid approval	USD 1.2 billion
Moderate	Delayed approval, slow market uptake	USD 600 million
Pessimistic	Unfavorable trial data, market rejection	USD 250 million

Risk Factors

• Clinical efficacy data, especially in resistant populations.
• Competitive pressure from other emerging non-covalent BTK inhibitors.
• Regulatory approval delays due to safety concerns.
• Market acceptance influenced by pricing and reimbursement policies.

Strategic Considerations

• Expansion opportunities include combination therapies with other targeted agents like venetoclax.
• Investment in biomarker development for patient stratification may improve trial success.
• Partnering with biotech firms can enhance clinical and commercial capabilities.

Timeline Outlook

Milestone	Expected Date
Ongoing Phase 3 trials ("BRUIN")	2023–2024
Preliminary trial results	2024–2025
Potential FDA submission	2025–2026
Possible approval	2026 or later

Conclusion

Pirtobrutinib remains in late-stage clinical development with promising potential to address therapy resistance in B-cell malignancies. Its market trajectory hinges on trial outcomes, competitive landscape evolution, and the ability to establish a niche within the non-covalent BTK inhibitor space. With an estimated market size of USD 8 billion for BTK therapies and rising demand for second-generation agents, the compound could generate significant revenues if successful.

Key Takeaways

• Pirtobrutinib is in Phase 3 trials targeting resistant B-cell malignancies.
• The global hematology-oncology market is growing at a CAGR of 8%, with BTK inhibitors representing a key segment.
• Market entry depends on successful trial data, regulatory approval, and competitive positioning.
• Estimated 5-year revenue potential ranges from USD 250 million to USD 1.2 billion, conditioned on clinical and commercialization success.
• Cost and investment focus on clinical development, with future gains contingent on trial outcomes and market receptivity.

FAQs

1. When could pirtobrutinib reach the market?
Pending trial results, FDA submission is targeted for 2025–2026, with potential approval in 2026 or later.

2. How does pirtobrutinib differ from existing BTK inhibitors?
It is a non-covalent inhibitor designed to bind BTK reversibly, potentially overcoming resistance mutations like C481S.

3. What are the primary competitors?
Ibrutinib, acalabrutinib, and zanubrutinib are covalent BTK inhibitors with established market share.

4. What indications are most promising for pirtobrutinib?
Relapsed/refractory CLL and MCL show the highest unmet needs. Resistance to covalent inhibitors further enhances its target profile.

5. What are the main risks for investment?
Clinical trial failure, regulatory hurdles, market competition, and reimbursement challenges.

---

References

[1] Eli Lilly. (2023). Pirtobrutinib (LOXO-305) Clinical Trial Data. [Online] Available at: [Company website]

[2] Market Research Future. (2022). Hematology Oncology Market Outlook.

[3] GlobalData. (2023). BTK Inhibitors Market Analysis.